ABL Bio's gastric cancer candidate shows tumor reduction in 79% of treated patients
Predicted impact: Medium
Clinical data on ABL111 already covered at ESMO this fortnight; 79% tumor reduction restates it.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.